Keywords
LA/corticosteroid; intra-articular injection; low back pain; lumbar facet joint syndrome; platelet-rich plasma.
Summary
46 eligible patients with lumbar facet joint syndrome were randomized into group A (intra-articular injection with PRP) and group B (intra-articular injection with LA/corticosteroid). The following contents were evaluated: pain visual analog scale (VAS) at rest and during flexion, and the Roland-Morris Disability Questionnaire (RMQ), Oswestry Disability Index (ODI), and modified MacNab criteria for pain relief and applications of post-treatment drugs. All outcome assessments were performed immediately after and at 1 week, 1, 2, 3, and 6 months after treatment.
For group B, subjective satisfaction based on the modified MacNab criteria and objective success rate were highest (80% and 85%) after 1 month, but only 50% and 20% after 6 months. However, for group A, they increased over time. In addition, there were no treatment-related complications in either group during follow-up.
Both autologous PRP and LA/corticosteroid for intra-articular injection are effective, easy, and safe enough in the treatment of lumbar facet joint syndrome. However, autologous PRP is a superior treatment option for longer duration efficacy.
Support available at Surecell
Our Surecell doctors are musculoskeletal experts who provide regenerative medicine treatments for osteoarthritis, such as platelet-rich plasma (PRP). Feel free to contact our friendly staff on 03 9822 9996 or submit an enquiry here.
Learn more about the treatments Surecell has to offer on our Services page.